Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Engaging in the Recommended Amount of Physical Activity May Help Prevent 7 Cancer Types

January 7, 2020
By Hannah Slater
Article

Though physical activity guidelines are largely based on chronic diseases like cardiovascular disease and diabetes, these data suggest they are important to cancer prevention as well.

According to a study published in the Journal of Clinical Oncology, engagement in the recommended amount of leisure-time physical activity (7.5-15 MET hours/week) was associated with lower risk for 7 different cancer types.1

While it has previously been known that physical activity is associated with a lower risk for several cancers, it was unclear if guideline recommended amounts of physical activity were associated with lower risk.2

“Physical activity guidelines have largely been based on their impact on chronic diseases like cardiovascular disease and diabetes,” Alpa Patel, PhD, senior scientific director of epidemiology research at the American Cancer Society, said in a press release. “These data provide strong support that these recommended levels are important to cancer prevention, as well.” 

In this cohort of 755,459 participants, individuals were followed for 10.1 years, and 50,620 incident cancers accrued during that time. Engagement in recommended amounts of activity were associated with a statistically significant lower risk for 7 of the 15 cancers studied, including colon (8%-14% lower risk in men), breast (6%-10% lower risk), endometrial (10%-18% lower risk), kidney (11%-17% lower risk), myeloma (14%-19% lower risk), liver (18%-27% lower risk), and non-Hodgkin lymphoma (11%-18% lower risk in women).

Both moderate- and vigorous-intensity activity seemed to be associated with lower risk for colon, breast, and kidney cancer, but the sample size for other cancer types was too limited to draw conclusive data. Adjustment for BMI eliminated the association with endometrial cancer but had a limited effect on other cancer types. 

Approximately half of the cancers associated with physical activity were found to have linear dose-response curves (colon, breast, endometrial, and head and neck cancer, as well as esophageal adenocarcinoma), with the lowest risk at levels well above the recommended minimum level of activity. For several cancers with a curvilinear association (kidney, gastric, and liver cancer), most of the risk reduction observed was associated with recommended amounts of physical activity. 

“This finding may explain in part previous observations that higher levels of activity were needed to achieve significantly lower risk of colon and breast cancer,” the authors wrote. “Given these linear associations, substantially lower relative risk estimates may have only been observable at higher activity levels in previous studies, particularly given smaller participant numbers and more limited statistical power in individual studies.” 

Additionally, the difference in the strength of associations for engaging in 7.5-15 MET hours/week when comparing results for breast cancer and liver cancer may reflect relevant differences in the underlying biologic mechanisms for distinct cancer types. These findings might indicate that there are fundamentally different physical activity dose-response relationships for all-cause and cardiovascular mortality and some cancers and sizable variation in the underlying biologic mechanisms that link physical activity to different types of cancer, however additional research is needed. 

Furthermore, researchers suggested that these findings provide actionable evidence for ongoing and future cancer prevention efforts, including the guidance that health care providers, fitness professionals, and public health practitioners should encourage adults to adopt and maintain physical activity at recommended levels.

References:

1. Matthews CE, Moore SC, Arem H, et al. Amount and Intensity of Leisure-Time Physical Activity and Lower Cancer Risk. Journal of Clinical Oncology. doi:10.1200/JCO.19.02407.

2. Report links recommended physical activity levels to lower risk of seven cancers [news release]. Published December 26, 2019. eurekalert.org/pub_releases/2019-12/acs-rlr122319.php. Accessed January 3, 2020.

Recent Videos
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Related Content
Advertisement

Results from the phase 3 VIKTORIA-1 trial showed gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival.

Gedatolisib Combos Improve PFS in Advanced PIK3CA Wild-Type Breast Cancer

Tim Cortese
July 29th 2025
Article

Results from the phase 3 VIKTORIA-1 trial showed gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival.


Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
July 28th 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.


Results from the phase 3 MATTERHORN trial support the FDA’s designations for durvalumab in gastric/gastroesophageal junction cancers.

Durvalumab Earns Priority Review, Breakthrough Status in Gastric Cancer

Roman Fabbricatore
July 28th 2025
Article

Results from the phase 3 MATTERHORN trial support the FDA’s designations for durvalumab in gastric/gastroesophageal junction cancers.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Results from the phase 3 GMMG-HD7 trial support the approval of the isatuximab-based combination in patients with newly diagnosed multiple myeloma.

Isatuximab Combo Approved in the EU for Transplant-Eligible NDMM

Roman Fabbricatore
July 25th 2025
Article

Results from the phase 3 GMMG-HD7 trial support the approval of the isatuximab-based combination in patients with newly diagnosed multiple myeloma.


Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Related Content
Advertisement

Results from the phase 3 VIKTORIA-1 trial showed gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival.

Gedatolisib Combos Improve PFS in Advanced PIK3CA Wild-Type Breast Cancer

Tim Cortese
July 29th 2025
Article

Results from the phase 3 VIKTORIA-1 trial showed gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival.


Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
July 28th 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.


Results from the phase 3 MATTERHORN trial support the FDA’s designations for durvalumab in gastric/gastroesophageal junction cancers.

Durvalumab Earns Priority Review, Breakthrough Status in Gastric Cancer

Roman Fabbricatore
July 28th 2025
Article

Results from the phase 3 MATTERHORN trial support the FDA’s designations for durvalumab in gastric/gastroesophageal junction cancers.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Results from the phase 3 GMMG-HD7 trial support the approval of the isatuximab-based combination in patients with newly diagnosed multiple myeloma.

Isatuximab Combo Approved in the EU for Transplant-Eligible NDMM

Roman Fabbricatore
July 25th 2025
Article

Results from the phase 3 GMMG-HD7 trial support the approval of the isatuximab-based combination in patients with newly diagnosed multiple myeloma.


Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.